|
KMID : 0378019910340120113
|
|
New Medical Journal
1991 Volume.34 No. 12 p.113 ~ p.118
|
|
|
Clinical Evaluation of Fortimicin^(®) in Infectious Diseas of Genitourinary Tract
|
|
|
|
|
Abstract
|
|
|
Urinary tract infections occur frequently, affect patients of all ages, and have a variety of presentations ranging from asymptomatic bacteriuria to severe life-threatening renal infections, abscess, and urosepsis. Infections caused by a virulent bacterium like pzoteus or pseudomonas, or infections in a compromised host or in a compromised urinary tract frequently are difficult to treat and are associated risk from urinary tract infecion constitute a major and rewarding challenge. Aminoglycosides consist of -two or more amino sugars joined via glycoside linkage to a contral hexose nucleus and are still the mainstay of urinary tract infection. But in setting in which resistance to old aminoglycosides and their toxicities is common, new aminoglycoside should be necessary. Fortimicin®, a new aminoglycoside antibiotic, is more potent and broadspectrum antibiotic and reduce the nephrotoxicity.
From July, 1991 to October, 1991, we evaluated the effectivity and the safety of Fortimicin® in 36 cases with urogenital tract infections.
The results as follows :
1. Symptomatic improvement was excellent in 24 cases (66.8%), good in 8 cases (22.2%), fair in 2 cases (5.5%) and poor in 2 cases (2.8%)
2. After treatment, pyuria was disappeared in 24 cases (66.8%), decreased in 11 cases (30.4%), no change in 1 case (2.8%).
3. Bacterial response of 30 cases that bacteria growed in urine culture was eradicated in 20 cases (66.6%), decreased in 5 cases (16.5%), not changed in 1 cases (3.3%) and replaced with new organism in 2 cases (6.6%).
4. There was no significant difference in subjective and laboratory findings for toxicity before and after treatment.
5. Efficacy was excellent in 23 cases (63.9%), good in 10 cases (27.8%), fair in 2 cases (5.5%) and poor in i case (2.8%).
So, Fortimicin® is a potent and safe aminoglycoside antibiotic in urogenital tract infections.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|